Spectral Diagnostics (EDTXF) Stock Price, News & Analysis

Company Overview

Spectral Medical Inc. focuses on the development and commercialization of products for the treatment of septic shock in the United States, Italy, Ireland, and internationally. The company markets Endotoxin Activity Assay, a rapid in vitro diagnostic test for the detection of components of gram negative bacterial cell wall; and Polymyxin B Hemoperfusion, a therapeutic hemoperfusion device that removes endotoxin from the bloodstream. It also develops and manufactures monoclonal and polyclonal antibodies, recombinant cardiac proteins, and calibrators for use in the research and development, as well as products that are manufactured by other diagnostic companies. The company was formerly known as Spectral Diagnostics Inc. and changed its name to Spectral Medical Inc. in December 2014. Spectral Medical Inc. was incorporated in 1991 and is headquartered in Toronto, Canada.

Key Stats

• Today's Range: $1.00 to $1.00
• 50-Day Range: $0.92 to $1.08
• 52-Week Range: $0.58 to $1.31
• Volume: 310 shs
• Average Volume: 9,441 shs
• Market Capitalization: $292.10 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Spectral Diagnostics Stock Analysis - MarketRank™

Spectral Diagnostics scored higher than 1% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Spectral Diagnostics.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Spectral Diagnostics is -9.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Spectral Diagnostics is -9.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.00% of the float of Spectral Diagnostics has been sold short.

Short Interest Ratio / Days to Cover

Spectral Diagnostics has a short interest ratio ("days to cover") of 0.22, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Spectral Diagnostics has recently increased by 5.21%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Spectral Diagnostics does not currently pay a dividend.

Dividend Growth

Spectral Diagnostics does not have a long track record of dividend growth.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Spectral Diagnostics this week, compared to 0 articles on an average week.

Company Ownership

• Score: 0.1 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Spectral Diagnostics insiders have not sold or bought any company stock.

Percentage Held by Insiders

1.50% of the stock of Spectral Diagnostics is held by insiders.

Percentage Held by Institutions

Spectral Diagnostics has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 5/08/2026
• Today: 6/03/2026
• Next Earnings (Estimated): 8/07/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: MED INSTRUMENTS
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:EDTXF
• Previous Symbol: OTCMKTS:DIAGF
• CIK: N/A
• Web: www.spectraldx.com
• Phone: (416) 626-3233
• Fax: 416-626-7383
• Employees: 29
• Year Founded: 1991

Profitability

• EPS (Trailing Twelve Months): ($0.10)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$34.13 million
• Net Margins: -1,378.12%
• Pretax Margin: -1,952.57%
• Return on Equity: N/A
• Return on Assets: -581.29%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.08
• Quick Ratio: 0.07

Sales & Book Value

• Annual Sales: $1.75 million
• Price / Sales: 166.91
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.17) per share
• Price / Book: -5.86

Miscellaneous

• Outstanding Shares: 293,419,000
• Free Float: 289,018,000
• Market Cap: $292.10 million
• Optionable: Not Optionable
• Beta: 0.09